Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

PURPOSE: Neoadjuvant chemotherapy for breast cancer provides critical information about tumor response; how best to leverage this for predicting recurrence-free survival (RFS) is not established. The I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and...

Full description

Saved in:
Bibliographic Details
Main Authors: Esserman, Laura J., Berry, Donald A., DeMichele, Angela, Carey, Lisa, Davis, Sarah E., Buxton, Meredith, Hudis, Cliff, Gray, Joe W., Perou, Charles, Yau, Christina, Livasy, Chad, Krontiras, Helen, Montgomery, Leslie, Tripathy, Debasish, Lehman, Constance, Liu, Minetta C., Olopade, Olufunmilayo I., Rugo, Hope S., Carpenter, John T., Dressler, Lynn, Chhieng, David, Singh, Baljit, Mies, Carolyn, Rabban, Joseph, Chen, Yunn-Yi, Giri, Dilip, van 't Veer, Laura, Hylton, Nola
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2012
Subjects:
Original Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3434983/
https://ncbi.nlm.nih.gov/pubmed/22649152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.39.2779
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items